RxDoctor Payments Data

Claudine San Gabriel

Acute Care · Torrance, CANPI 1134903404

Payments from drug & device makers

$1,682in general payments, 2019–2025

Across 69 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$305
  • Boehringer Ingelheim$289
  • Novartis$254
  • Bayer$145
  • Kiniksa Pharmaceuticals International, PLC$102
  • Inspire Medical Systems, Inc.$83
  • plus $504 from 15 others

What the payments were for

  • Food & beverage$1,682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,682 in reported general payments places this provider in the 80th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$7,457
Medicare patients
71
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$94,166
JardianceEmpagliflozin62$52,284
EntrestoSacubitril/Valsartan35$42,014
FarxigaDapagliflozin Propanediol12$8,273
Ranolazine ErRanolazine20$1,568
Hydralazine Hcl116$1,354
Ezetimibe39$991
Metoprolol Succinate55$902
Losartan Potassium74$682
Olmesartan Medoxomil25$673
Amlodipine Besylate105$586
Diltiazem Hcl17$581
Atorvastatin Calcium54$523
Nifedipine ErNifedipine11$400
Lisinopril42$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$289$52,28462 claims
NovartisEntresto$254$42,01435 claims
AstraZenecaFarxiga$75$8,27312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,153 acute care providers in California.

Other acute care in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →